Global Brain Mapping Instruments Market Size & Growth Trends Analysis Report

The rising incidence of neurological diseases including Parkinson's disease, Alzheimer's disease, and other cognitive impairments around the globe is one of the main reasons driving the need for brain mapping techniques. These disorders are becoming increasingly prevalent as the world's population ages, which increases the demand for sophisticated diagnostic instruments to identify and track brain health. The technologies for brain mapping offer vital information on the structure and activity of the brain, which helps with early diagnosis and treatment of various disorders. Brain mapping methods are crucial for researchers and doctors since early diagnosis is crucial to bettering patient outcomes. The market's expansion has been significantly aided by the creation and use of non-invasive brain mapping methods including functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG). These technologies eliminate the need for intrusive operations like surgery by enabling detailed, real-time mapping of brain activity. For instance, fMRI is frequently used to observe brain activity in both clinical and research contexts, whereas MEG has the capability of measuring the magnetic fields produced by neuronal activity. The use of these methods in the diagnosis, observation, and research of neurological illnesses keeps growing as they become more sophisticated and widely available. The European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and other regional healthcare agencies are important regulatory bodies that monitor the market.

The need for more effective diagnostic tools is being driven by rising healthcare expenses, and brain mapping technologies are being considered as a possible remedy. Brain mapping techniques can lower the long-term treatment expenses of neurological illnesses by facilitating earlier identification and more precise diagnoses. Furthermore, continuous developments in imaging technology are enhancing brain mapping's speed, accuracy, and resolution, increasing the usefulness and accessibility of these techniques. The development of imaging equipment, such as more portable and reasonably priced models, contributes to the market's expansion. Furthermore, more people are using brain mapping tools due to increased awareness of mental health issues and the value of early detection.

The market for brain mapping instruments is constrained by factors including the high expense of sophisticated brain mapping technology and a lack of qualified personnel to handle these sophisticated instruments. The growth may also be impeded by restricted reimbursement policies in some areas for brain mapping treatments. However, the incorporation of machine learning (ML) and artificial intelligence (AI) into brain mapping technology creates new avenues for improved diagnosis speed and accuracy. The developing emerging market’s healthcare infrastructure offers enormous growth possibilities as well.

Impact of COVID-19

The COVID-19 pandemic had a conflicting effect on the market for brain mapping tools. On the one hand, the pandemic caused supply chain disruptions, postponed elective surgeries, and decreased hospital visits, which temporarily decreased the need for non-urgent diagnostic tools like brain mapping equipment. The management of the pandemic took up a lot of healthcare resources, which had an impact on research and development efforts about neurological diagnoses.

However, the pandemic also brought attention to the significance of mental health, as evidenced by the rise in cases of anxiety, depression, and other neurological disorders brought on by the stress and isolation of the crisis. This raised public awareness of neurological health, which in turn raised the need for brain mapping technologies over the long run. Furthermore, the pandemic's advances in telemedicine and remote diagnostics opened up new possibilities for the use of brain imaging technologies in virtual healthcare environments.

Overall, despite some immediate difficulties, the market for brain mapping tools has a promising future due to the growing emphasis on neurological and mental health research.

Segmentation

The global market for brain mapping tools is segmented into technology, application, and end user. By technology, the global brain mapping instruments market is segmented into near-infrared spectroscopy (NIRS), functional magnetic resonance imaging (fMRI), magnetoencephalography (MEG), and electroencephalography (EEG). Companies such as Medtronic and Natus Medical do well in the EEG market; Compumedics and Elekta are at the forefront in the MEG market.

By application, the market is segmented into drug discovery, research, and clinical diagnostics. Offering cutting-edge imaging technologies like fMRI for neurological studies, GE Healthcare and Siemens Healthineers are prominent players in the research and drug discovery sectors. Brain Products GmbH and Nihon Kohden are leaders in clinical diagnostics, offering instruments for the diagnosis of epilepsy, dementia, and other conditions.

By end user, the global brain mapping instruments market is divided into academic institutions, hospitals, and research centers. Universities and research centers are important end customers, and businesses like Thermo Fisher Scientific and Philips Healthcare provide cutting-edge equipment for academic study. On the other hand, for real-time brain monitoring and diagnostics, hospitals are heavily dependent on systems from Masimo and Canon Medical Systems.

Regional Analysis

The market for brain mapping tools is growing in diverse ways in different parts of the world. Owing to its sophisticated healthcare system, high healthcare spending, and substantial investment in neurological research, North America has the highest market share in 2023. With major competitors like Medtronic, GE Healthcare, and NeuroPace controlling the market, the U.S. leads the region in particular. The demand is also fuelled by the increased frequency of neurological conditions and the large number of clinical studies for illnesses relating to the brain.

Driven by technology improvements and a heavy emphasis on mental health awareness, Europe follows closely behind North America. The leading contributors include the UK, France, and Germany, and suppliers of cutting-edge brain mapping technologies include Siemens Healthineers and Elekta. The government policies that are supportive and increased spending for healthcare provide additional impetus for market expansion in this region.

Due to the region's significant improvements in healthcare infrastructure, rising rates of neurological disorders, and increased emphasis on research and development, Asia-Pacific is predicted to rise at the quickest rate in the upcoming years. Brain mapping technologies are in high demand in countries like China, Japan, and India, where businesses like NeuroSky and Nihon Kohden are growing their footprints. The growth of the industry is also aided by government programs to enhance healthcare provision and raise public awareness of mental health issues.

While still in its infancy, the market in Latin America and the Middle East and Africa has room to grow. The demand is driven by rising investments in medical technologies and improved healthcare systems in emerging nations including Brazil, South Africa, and the United Arab Emirates. Nonetheless, these areas face difficulties due to a lack of adequate healthcare infrastructure and a lack of knowledge about brain mapping technologies.

Competitive Analysis

The key players in the global brain mapping instruments market are Medtronic, GE HealthCare, Koninklijke Philips N.V., Siemens Healthcare Private Limited, Advanced Brain Monitoring Inc., Natus, BrainScope Company Inc., Brain Products GmbH, Compumedics Limited, and Nihon Kohden Corporation, among others. Moreover, startups like Kernel, which specializes in non-invasive brain mapping technologies, and Paradromics, which is well-known for its neural interfaces are gaining ground and succeeding.

The FDA approved Medtronic plc's Percept RC Deep Brain Stimulation (DBS) system in January 2024, adding a rechargeable neurostimulator with BrainSense technology to the Percept portfolio, which also included the Percept PC neurostimulator and SenSight-directed leads. Similarly, Brain Products GmbH introduced BrainVision Analyser 2.3.0.8301, a software program for handling and evaluating ERP and EEG data, in July 2024. The program helps with scientific and software requirements, supports more than 50 data types, and provides a bidirectional connection to MATLAB.

For the Table of Contents (TOC) of the entire report, Contact Us. We will provide you with the full TOC for the same.

The global brain mapping instruments market is segmented as follows:

By Technology (Revenue: USD Billion, 2019 – 2031)
●    Near-Infrared Spectroscopy (NIRS)
●    Functional Magnetic Resonance Imaging (fMRI)
●    Magnetoencephalography (MEG)
●    Electroencephalography (EEG)

By Application (Revenue: USD Billion, 2019 – 2031)
●    Drug Discovery
●    Research
●    Clinical Diagnostics

By End User (Revenue: USD Billion, 2019 – 2031)
●    Academic Institutions
●    Hospitals
●    Research Centers

By Region (Revenue: USD Billion, 2019 – 2031)

● North America
o U.S.
o Canada
o Mexico

● Europe
o U.K.
o France
o Germany
o Italy
o Spain
o Rest of Europe

● Asia Pacific
o China
o Japan
o India
o South Korea
o South East Asia
o Rest of Asia Pacific

● Latin America
o Brazil
o Argentina
o Rest of Latin America

● Middle East & Africa
o GCC Countries
o South Africa
o Rest of Middle East & Africa